Hu, Nan

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy

Liu, J., Li, S., Wang, Q., Feng, Y., Xing, H., Yang, X., Guo, Y., Guo, Y., Sun, H., Liu, X., et al. (2024) · Blood

Cell death mechanisms and regulationChronic Lymphocytic Leukemia Research

Cited by 76

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 65

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

Flinsenberg, T. W. H., Tromedjo, C. C., Hu, N., Liu, Y., Guo, Y., Thia, K. Y. T., Noori, T., Song, X., Aw Yeang, H. X., Tantalo, D. G., et al. (2020) · Haematologica

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 56

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Carbone, D. P., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Felip, E., Cheng, Y., Juan-Vidal, O., et al. (2025) · ESMO Open

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 43